Hye-Jung E

Sep 17, 2024 | aacrjournals.org | Hye-Jung E |Inselspital Bern |Biomedical Informatics

Extracranial malignant rhabdoid tumors (eMRT) are a challenging entity. Despite the use of multimodal treatment approaches, therapy failure occurs in 55% to 67% of these. Molecular markers for identification of patients at increased risk for relapse or refractory (R/R) disease are not available. Clinical characteristics may only insufficiently predict the individual course of disease. Using the EU-RHAB database, we analyzed a cohort of 121 patients with eMRT clinically.

Aug 9, 2024 | aacrjournals.org | Homburg Saar |Hye-Jung E

Purpose: Extracranial malignant rhabdoid tumors (eMRT) are a challenging entity. Despite the use of multimodal treatment approaches, therapy failure occurs in 55-67%. Molecular markers for identification of patients at increased risk for relapse or refractory (R/R) disease are not available. Clinical characteristics may only insufficiently predict the individual course of disease. Experimental Design: Using the EU-RHAB database, we analyzed a cohort of 121 patients with eMRT clinically.